The Ifakara Health Institute has on January 17, 2012 started the first phase II study aimed to develop a vaccine against tuberculosis (TB). The study is an initiative of IHI’s collaboration with the Statens Serum Institut, the Aurum Institute, the Swiss Tropical and Public Health Institute, and the South African TB Vaccine Initiative. The randomised, double-blind, clinical trial is funded by the European and Developing Countries Clinical Trials Partnership (EDCTP) and aims to assess immunogenicity and safety of a novel tuberculosis subunit vaccine candidate (Ag85B-ESAT-6) and the IC31® adjuvant. First results are expected in 2013. The existing Bacillus Calmette-Guérin (BCG) vaccine is a live vaccine that, when given to newborns, provides partial protection against TB in the first decade of life. However, BCG does not prevent adult pulmonary disease satisfactorily and therefore has not reduced the global burden of tuberculosis. Consequently, the development of a new efficient, safe and affordable TB vaccine remains a global priority. |
|
Announcements >
Ifakara Health Institute launches a phase II TB vaccine trialposted 21 Jan 2012 14:43 by IHI Webmaster [ updated 21 Jan 2012 14:52 ] |
© IFAKARA Health Institute (IHI), 2011 Site Visitors